Opexa, Merck Serono Ink Creative Deal for MS Therapy
The up-front payment was just $5 million, but a potential $225 million option and licensing deal between Opexa Therapeutics Inc. and Merck Serono SA to develop and commercialize Tcelna (imilecleucel-T), a personalized T-cell immunotherapy in multiple sclerosis (MS), could offer a win-win for the small biotech and Merck Serono, if the product crosses the finish line.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST